As healthy ageing shifts from trend to growth driver, brands face a clear choice: build products grounded in clinical evidence and regulatory rigour – backed by science, not slogans
Longevity, to me, is no longer about chasing mythical “anti-aging” miracles. It is about something far more grounded and meaningful: helping people add more years of mobility, clarity, and vitality — years they can truly live in. In my role at the helm of a science-first organisation, I see healthy aging not as a trend but as a structural growth driver for the global FMCG and nutrition industries. Nowhere is this more evident than in the UK, where highly discerning regulators and consumers increasingly demand proof, not promises.
Modern science has made one thing abundantly clear: aging is driven by identifiable, modifiable biological processes, including chronic low-grade inflammation, oxidative stress, mitochondrial decline, sarcopenia, insulin dysregulation, and shifts in the microbiome. Nutrition cannot stop aging, but it can move the needle. Landmark cohort studies — from the UK Biobank to NIH-backed longitudinal analyses — consistently show that individuals with diets rich in polyphenols, bioactives, and plant-derived metabolites enjoy better physical function, slower cognitive decline, and reduced risk of chronic disease. In fact, diets high in botanical polyphenols are associated with a 30–35 percent lower incidence of age-related functional decline.
This is the foundation on which Sabinsa’s botanical & microbiome innovation sits: standardising nature’s complexity into reproducible, clinically validated ingredients that FMCG brands can trust.
Pillar 1: cellular & metabolic longevity — turning evidence into everyday impact
Curcumin C3 Complex® and its successor C3 Reduct® demonstrate how credible longevity science should work. C3 Complex®, standardised for reproducible curcuminoid ratios, has been used in more than 100 published studies, establishing a robust body of evidence for its effects on inflammatory balance and antioxidant capacity. Meanwhile, C3 Reduct® — with its tetrahydrocurcuminoid metabolites — offers up to 5x higher stability and greater reductive potential, making it exceptionally relevant for healthy aging.
Real-world outcomes matter, and in randomised controlled trials with older adults, curcuminoid supplementation led to measurable gains in lower-limb strength and gait speed and reduced inflammatory markers. These were modest shifts, but the kind that help people maintain independence longer.
Saberry® (from amla) provides documented antioxidant activity with β-glucogallin standardisation. At the same time, Sabeet® (from beet roots), a natural nitrate source, reflects the growing evidence on nitric oxide’s role in supporting vascular function — areas where consumers increasingly expect FMCG products to deliver functional value. LivLonga® (a combination of 95 percent curcuminoids, 20 percent garcinol, and 95 percent piperine) targeting hepatic inflammation and metabolic flexibility fits the same paradigm: longevity begins with how effectively your body handles stressors at the cellular level.
Pillar 2: gut microbiome & immune resilience — the ‘New FMCG Battleground’
Gut health is no longer optional in aging science — it’s central. Up to 70 percent of immune activity is linked to the gut, and age-driven microbiome shifts are now recognised as predictors of frailty, mood disturbance, and metabolic risk.
Our probiotic LactoSpore® (H. coagulans MTCC 5856) is an industry workhorse precisely because it delivers outcomes that matter to consumers: reduced bloating, discomfort, and irregularity, along with better quality-of-life indices — all demonstrated in controlled studies and at practical FMCG-friendly doses. It is also heat-stable and shelf-stable, enabling use in beverages, bars, powders, confectionery, and other mainstream formats. For FMCG players, stability equals scalability.
The future, however, is moving toward postbiotics, which are safe, regulator-friendly, and highly manufacturable. Our PoZibio® (L. paracasei) and ImmunoSpore® (heat-inactivated spores of H. coagulans MTCC 5856) platforms reflect this direction: non-viable microbial components that deliver consistent immunological and digestive benefits without cold-chain constraints. This is precisely the type of solution global regulators are favouring as they tighten probiotic efficacy and labeling rules.
Pillar 3: neurocognitive function & stress resilience — the most underserved longevity need
Cognition is the new heart health. With nearly one in four UK consumers reporting stress-related cognitive strain, FMCG brands are under pressure to deliver functional solutions that are safe, subtle, and suitable for daily consumption.
Ashwagandha root extract — represented in our USP-grade Shagandha® — has shown benefits across memory, focus, sleep quality, cortisol reduction, and overall well-being. These outcomes are not fringe science. Meta-analyses show 20–30 percent improvements in perceived stress scores and meaningful gains in working memory and sleep efficiency. When you connect this with research linking chronic stress to cardiometabolic decline and neurodegeneration, the longevity relevance becomes obvious.
In my view, this category will define the next wave of FMCG innovation. Consumers no longer want stimulants or mood gimmicks; they want ingredients that make them more resilient, more focused, and more able to function in a demanding world.
Three decades in the trenches: what longevity innovation must stand for
Across my years growing Sabinsa into a global enterprise — spanning R&D, supply chain, IP, regulatory compliance, clinical research, and multinational FMCG partnerships — one lesson has stayed constant: longevity products must sit at the intersection of credible science, uncompromising quality, and honest communication.
The market is flooded with “anti-aging” noise. But noise doesn’t win consumer trust; demonstrated outcomes do.
For UK FMCG companies, this creates a clear competitive opportunity: integrate clinically substantiated, regulator-vetted ingredients into products people already purchase daily, such as teas, beverages, fortified foods, shots, functional snacks, vitamins, and ready-to-go formats.
The brands that win longevity will be the ones that:
– Commit to clinically validated ingredients with transparent standardization.
– Communicate benefits without exaggeration.
– Adopt longevity as a design principle, not a headline.
– Anchor innovation in measurable consumer impact.
Sabinsa’s portfolio of C3 Complex®, C3 Reduct®, LactoSpore®, Saberry®, LivLonga®, PoZibio®, ImmunoSpore®, Shagandha®, and more exists precisely to support this next generation of FMCG products.
Longevity is no longer a future ambition. It is the organising principle for the next decade of health-focused consumer goods.
Dr. Shaheen Majeed is the Global CEO of Sami-Sabinsa Group
